New Delhi: Pathology laboratory chain, Metropolis Healthcare ended the third quarter of fiscal yr with a revenue of Rs 406 crore, up 26 per cent on year-on-yea (YoY) foundation.
Ebitda for the quarter stood at Rs 95 crore, whereas web revenue jumped 63 per cent YoY to Rs 51 crore.
In Q3, B2B revenue grew 35 per cent YoY, and revenue from direct to shopper choices expanded 19 per cent from the yr in the past quarter.
Revenue per check (RPT) and revenue per affected person (RPP) elevated 11 per cent and 10 per cent YoY, respectively, pushed by greater adoption of superior diagnostics.
Affected person and check volumes continued their constructive trajectory, rising 14 per cent and 13 per cent YoY, respectively.
The corporate has accomplished the mixing of its latest acquisitions and reported continued outperformance from Scientific Pathology (Agra), Dr. Ahuja’s Pathology & Imaging Heart (Dehradun), and Dr. R. S. Patil’s Ambika Pathology Laboratory (Kolhapur).
“Our Q3 efficiency displays how Metropolis is capturing these alternatives in Tier II and Tier III markets by way of a transparent strategic focus and sustained investments in specialised capabilities,” mentioned Ameera Shah, Promoter and Govt Chairperson, Metropolis Healthcare Restricted.
Source link
#Metropolis #FY26 #revenue #rises
